FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019157831> ?p ?o ?g. }

• W2019157831 endingPage "270" @default.
• W2019157831 startingPage "262" @default.
• W2019157831 abstract "Short-term trials have demonstrated the efficacy and safety of combination therapy using antimuscarinics and α-blockers in men with lower urinary tract symptoms (LUTS). The Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS (oral controlled absorption system) in Males with Lower Urinary Tract Symptoms (NEPTUNE) II is the first long-term study using solifenacin (Soli) and the oral controlled absorption system formulation of tamsulosin (TOCAS). To evaluate long-term (up to 52 wk) safety and efficacy of flexible dosing of two fixed-dose combinations (FDC) of Soli plus TOCAS in men with moderate to severe storage symptoms and voiding symptoms. Patients with both storage and voiding LUTS, maximum urinary flow rate of 4.0–12.0 ml/s, prostate size <75 ml, and postvoid residuals ≤150 ml, who completed the 12-wk, double-blind NEPTUNE study could continue in the 40-wk, open-label NEPTUNE II study. FDC of Soli 6 mg plus TOCAS 0.4 mg, or Soli 9 mg plus TOCAS 0.4 mg; patients could switch between doses in NEPTUNE II. Safety and efficacy data from NEPTUNE and NEPTUNE II were combined to cover a 52-wk period. Primary efficacy end points were total International Prostate Symptom Score (IPSS) and total urgency and frequency score (TUFS); secondary end points included IPSS storage and voiding subscores, micturition diary variables, and quality of life parameters. In all, 1066 men completed NEPTUNE and received one dose or more of study medication in NEPTUNE II. Treatment-emergent adverse events were reported in 499 (46.8%) patients who participated in NEPTUNE II; most were mild or moderate. Urinary retention occurred in 13 of 1208 (1.1%) patients receiving one or more FDCs in NEPTUNE and/or NEPTUNE II; 8 (0.7%) required catheterisation (acute urinary retention [AUR]). Reductions in total IPSS and TUFS during NEPTUNE were maintained for up to 52 wk of FDC treatment, with mean reductions of 9.0 (standard deviation [SD]: 5.7) and 10.1 (SD: 9.2), respectively, from baseline to end of treatment. Clinically relevant improvements were also observed for secondary efficacy end points. Long-term treatment with FDC Soli plus TOCAS was well tolerated and efficacious in men with storage and voiding LUTS, with a low incidence of AUR. Treatment with solifenacin plus tamsulosin in a fixed-dose combination tablet was well tolerated by men with lower urinary tract symptoms. Improvements in symptoms were achieved after 4 wk of treatment, with further improvements at week 16 maintained for up to 52 wk throughout the study." @default.
• W2019157831 created "2016-06-24" @default.
• W2019157831 creator A5002038596 @default.
• W2019157831 creator A5009422584 @default.
• W2019157831 creator A5011288509 @default.
• W2019157831 creator A5027594088 @default.
• W2019157831 creator A5043068037 @default.
• W2019157831 creator A5065742626 @default.
• W2019157831 creator A5080266362 @default.
• W2019157831 creator A5081498366 @default.
• W2019157831 date "2015-02-01" @default.
• W2019157831 modified "2023-09-27" @default.
• W2019157831 title "Long-term Safety and Efficacy of Single-tablet Combinations of Solifenacin and Tamsulosin Oral Controlled Absorption System in Men with Storage and Voiding Lower Urinary Tract Symptoms: Results from the NEPTUNE Study and NEPTUNE II Open-label Extension" @default.
• W2019157831 cites W1925228685 @default.
• W2019157831 cites W1967312126 @default.
• W2019157831 cites W2011962188 @default.
• W2019157831 cites W2016630371 @default.
• W2019157831 cites W2018377518 @default.
• W2019157831 cites W2032126389 @default.
• W2019157831 cites W2057645456 @default.
• W2019157831 cites W2078160609 @default.
• W2019157831 cites W2079938318 @default.
• W2019157831 cites W2132044709 @default.
• W2019157831 cites W2132697170 @default.
• W2019157831 cites W2146458227 @default.
• W2019157831 cites W2161995988 @default.
• W2019157831 cites W2164869770 @default.
• W2019157831 cites W2318854599 @default.
• W2019157831 doi "https://doi.org/10.1016/j.eururo.2014.07.013" @default.
• W2019157831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25070148" @default.
• W2019157831 hasPublicationYear "2015" @default.
• W2019157831 type Work @default.
• W2019157831 sameAs 2019157831 @default.
• W2019157831 citedByCount "62" @default.
• W2019157831 countsByYear W20191578312014 @default.
• W2019157831 countsByYear W20191578312015 @default.
• W2019157831 countsByYear W20191578312016 @default.
• W2019157831 countsByYear W20191578312017 @default.
• W2019157831 countsByYear W20191578312018 @default.
• W2019157831 countsByYear W20191578312019 @default.
• W2019157831 countsByYear W20191578312020 @default.
• W2019157831 countsByYear W20191578312021 @default.
• W2019157831 countsByYear W20191578312022 @default.
• W2019157831 countsByYear W20191578312023 @default.
• W2019157831 crossrefType "journal-article" @default.
• W2019157831 hasAuthorship W2019157831A5002038596 @default.
• W2019157831 hasAuthorship W2019157831A5009422584 @default.
• W2019157831 hasAuthorship W2019157831A5011288509 @default.
• W2019157831 hasAuthorship W2019157831A5027594088 @default.
• W2019157831 hasAuthorship W2019157831A5043068037 @default.
• W2019157831 hasAuthorship W2019157831A5065742626 @default.
• W2019157831 hasAuthorship W2019157831A5080266362 @default.
• W2019157831 hasAuthorship W2019157831A5081498366 @default.
• W2019157831 hasConcept C121608353 @default.
• W2019157831 hasConcept C126322002 @default.
• W2019157831 hasConcept C126894567 @default.
• W2019157831 hasConcept C142724271 @default.
• W2019157831 hasConcept C204787440 @default.
• W2019157831 hasConcept C2776235491 @default.
• W2019157831 hasConcept C2776547966 @default.
• W2019157831 hasConcept C2777562237 @default.
• W2019157831 hasConcept C2778941218 @default.
• W2019157831 hasConcept C2779478474 @default.
• W2019157831 hasConcept C2779502394 @default.
• W2019157831 hasConcept C2780542891 @default.
• W2019157831 hasConcept C71924100 @default.
• W2019157831 hasConcept C77411442 @default.
• W2019157831 hasConceptScore W2019157831C121608353 @default.
• W2019157831 hasConceptScore W2019157831C126322002 @default.
• W2019157831 hasConceptScore W2019157831C126894567 @default.
• W2019157831 hasConceptScore W2019157831C142724271 @default.
• W2019157831 hasConceptScore W2019157831C204787440 @default.
• W2019157831 hasConceptScore W2019157831C2776235491 @default.
• W2019157831 hasConceptScore W2019157831C2776547966 @default.
• W2019157831 hasConceptScore W2019157831C2777562237 @default.
• W2019157831 hasConceptScore W2019157831C2778941218 @default.
• W2019157831 hasConceptScore W2019157831C2779478474 @default.
• W2019157831 hasConceptScore W2019157831C2779502394 @default.
• W2019157831 hasConceptScore W2019157831C2780542891 @default.
• W2019157831 hasConceptScore W2019157831C71924100 @default.
• W2019157831 hasConceptScore W2019157831C77411442 @default.
• W2019157831 hasIssue "2" @default.
• W2019157831 hasLocation W20191578311 @default.
• W2019157831 hasLocation W20191578312 @default.
• W2019157831 hasOpenAccess W2019157831 @default.
• W2019157831 hasPrimaryLocation W20191578311 @default.
• W2019157831 hasRelatedWork W1529168523 @default.
• W2019157831 hasRelatedWork W1967030306 @default.
• W2019157831 hasRelatedWork W2008344118 @default.
• W2019157831 hasRelatedWork W2037427073 @default.
• W2019157831 hasRelatedWork W2141784075 @default.
• W2019157831 hasRelatedWork W2319841555 @default.
• W2019157831 hasRelatedWork W2389841854 @default.
• W2019157831 hasRelatedWork W2510528922 @default.
• W2019157831 hasRelatedWork W3113231186 @default.
• W2019157831 hasRelatedWork W2461170390 @default.
• W2019157831 hasVolume "67" @default.
• W2019157831 isParatext "false" @default.

• next